Novavax Retained Earnings (Accumulated Deficit) 2010-2024 | NVAX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Novavax retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Novavax Retained Earnings (Accumulated Deficit) 2010-2024 | NVAX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Novavax retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.8B
Vertex Pharmaceuticals (VRTX)	$133.1B
Gilead Sciences (GILD)	$120.2B
Bristol Myers Squibb (BMY)	$109.8B
Regeneron Pharmaceuticals (REGN)	$91B
CSL (CSLLY)	$90.5B
GSK (GSK)	$75.2B
Alnylam Pharmaceuticals (ALNY)	$35.8B
Argenex SE (ARGX)	$35.6B
BioNTech SE (BNTX)	$26.3B
Biogen (BIIB)	$25.2B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$18B
Incyte (INCY)	$16.1B
Genmab (GMAB)	$15.3B
Vaxcyte (PCVX)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.8B
Bio-Techne Corp (TECH)	$12.1B
Sarepta Therapeutics (SRPT)	$11.6B
Exelixis (EXEL)	$10.4B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.8B
Repligen (RGEN)	$7.9B
Halozyme Therapeutics (HALO)	$7.8B